Lilly starts second phase 3 adolescent obesity trial with comorbidity endpoint

Eli Lilly has started a second phase 3 obesity trial in adolescents, and this one is built around whether weight-related health conditions get better, not only how much weight participants lose. The study, called SURMOUNT-ADOLESCENTS-2, is registered on ClinicalTrials.gov as NCT06439277 and plans to enroll 300 people aged 12 to 17 who have obesity along with multiple weight-related conditions ^[1].

The trial has two co-primary endpoints, meaning its main results depend on how it performs on both. The first is percent change in body mass index at week 72, a standard measure in obesity research ^[1]. The second is a composite endpoint: a participant must reach normalization or a clinically meaningful improvement in at least two predefined weight-related conditions, and must not develop any new ones ^[1].

That pairing sets a higher bar than a weight measurement alone. Under the composite, a participant who loses weight but whose related conditions stay the same — or who develops a new one — does not count as a success on that endpoint. Both endpoints are listed as co-primary, so the trial is not designed to succeed on BMI change by itself ^[1].

Primary completion, the point at which the last participant is expected to finish the main measurement period, is listed as October 2027 ^[1]. The registry entry does not name the specific conditions on the predefined list, does not spell out how improvement in each condition is defined, and does not describe the trial's secondary endpoints. Those details have not been reported.

According to the registry entry, this is Lilly's second phase 3 trial in adolescent obesity, following an earlier study in the same age group ^[1]. The record does not indicate where the trial sites are located, how participants are assigned to treatment groups, or whether the study compares the treatment against a placebo.

Why it matters for patients

For a teenager with obesity and related health problems, the question families often care about most is not what a scale reads but whether conditions such as high blood pressure, high blood sugar or sleep apnea actually improve. SURMOUNT-ADOLESCENTS-2 is designed to test that question directly, with a co-primary endpoint that requires measurable improvement in at least two existing conditions and no new ones ^[1].

That design matters for how any future results should be read. A trial that hits its BMI endpoint but misses the comorbidity endpoint would send a mixed signal, and the reverse is also possible. Because both measures are co-primary, neither can be quietly set aside when the data are reported ^[1].

It also matters that the trial is enrolling 12- to 17-year-olds with multiple weight-related conditions rather than adolescents with obesity alone ^[1]. Findings from that group may not apply to teenagers who have obesity but no other diagnosed conditions, or to children outside that age range. No conclusion about whether the treatment works can be drawn now; the trial is still enrolling and the primary completion date is more than three years away ^[1].

What happens next

The next publicly listed milestone is primary completion in October 2027 ^[1]. Whether results will be published in a medical journal, presented at a conference, or posted directly to the trial registry has not been reported. The registry entry also does not list any interim analysis dates, so no earlier readout of the co-primary endpoints has been disclosed ^[1].

Until results are available, the trial's design is the main piece of information families and clinicians have. The full list of predefined comorbidities and the thresholds that define meaningful improvement in each are expected to appear in the study protocol, which has not been made public in the registry entry ^[1].